Alvine gobbles $21.5M to treat gastrointestinal disease
Alvine Pharmaceuticals, developer of drugs for autoimmune and gastrointestinal diseases, has raised $21.5 million more in first-round funding, bringing the total to $47.5 million. The San Carlos, Calif. received the expansion from Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.
Alvine Pharmaceuticals raises $26 million for disease research
San Carlos, Calif. company Alvine Pharmaceuticals recently added $5 million to its first venture round, bringing total funding to $26 million, according to VentureWire.
Alvine’s research focuses on treatment for autoimmune and gastrointestinal diseases, and it started clinical trials in February for its treatment of celiac sprue, a condition that stems from the inability to process gluten. Backers include Cargill Ventures, Flagship Ventures, InterWest Partners, Prospect Venture Partners and Sofinnova Ventures.